Abstract:<h3 class="a-plus-plus">Abstract</h3> <p class="a-plus-plus">Lower-extremity arterial disease (LEAD) is a major endemic disease with an alarming increased prevalence worldwide. It is a common and severe condition with excess risk of major cardiovascular events and death. It also leads to a high rate of lower-limb adverse events and non-traumatic amputation. The American Diabetes Association recommends a widespread medical history and clinical examination to screen for LEAD. The ankle brachial index (ABI) is the first non-invasive tool recommended to diagnose LEAD although its variable performance in patients with diabetes. The performance of ABI is particularly affected by the presence of peripheral neuropathy, medial arterial calcification, and incompressible arteries. There is no strong evidence today to support an alternative test for LEAD diagnosis in these conditions. The management of LEAD requires a strict control of cardiovascular risk factors including diabetes, hypertension, and dyslipidaemia. The benefit of intensive versus standard glucose control on the risk of LEAD has not been clearly established. Antihypertensive, lipid-lowering, and antiplatelet agents are obviously worthfull to reduce major cardiovascular adverse events, but few randomised controlled trials (RCTs) have evaluated the benefits of these treatments in terms of LEAD and its related adverse events. Smoking cessation, physical activity, supervised walking rehabilitation and healthy diet are also crucial in LEAD management. Several advances have been achieved in endovascular and surgical revascularization procedures, with obvious improvement in LEAD management. The revascularization strategy should take into account several factors including anatomical localizations of lesions, medical history of each patients and operator experience. Further studies, especially RCTs, are needed to evaluate the interest of different therapeutic strategies on the occurrence and progression of LEAD and its related adverse events in patients with diabetes.</p>

Current status and challenges over interventional treatment of lower limb arterial diseases

Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus

Progress on Coverage and Reconstruction of Left Subclavian Artery in Thoracic Endovascular Aortic Repair

Successful Endovascular Treatment of Popliteal Artery Entrapment Syndrome: A Case Report with 3-Years Follow-Up

[Progress and prospect of the treatment of lower extremity arteriosclerosis obliterans].

Endovascular revascularization vs. open surgical revascularization for patients with lower extremity artery disease: a systematic review and meta-analysis

Endovascular treatment of lower extremity arteriosclerosis obliterans of TASC-D type：its current clinical situation

[Analysis of Cause and Treatment of Acute Limb Ischemia Complicated in Peripheral Endovascular Interventions].

Current developments in endovascular therapy of peripheral vascular disease

[The study on the isolation of enterohemorrhagic Escherichia coli 0111 from meat samples using immunomagnetic beads].

Endovascular intervention for tibial artery occlusive disease in patients with critical limb ischemia

Diagnosis and Treatment of Lower Extremity Vascular Injury

Endovascular therapy of long occlusive femoral artery

Analysis of Results of the Below-the-knee Endovascular Therapy for Critical Limb Ischemia

Lower extremity arterial disease in patients with diabetes: a contemporary narrative review

Progress in Application of Intravascular Ultrasound in Lower Extremity Artery Disease

[Progress and prospect of excimer laser ablation in the treatment of therosclerotic obliterans].

Systems-on-Chip on FPGAs

Endovascular treatment of femoropopliteal atherosclerotic occlusive disease

Clinical application of endovascular interventional therapy in the treatment of diabetic foot

Current Status of and Future Prospects for Drug-Eluting Stents and Scaffolds in Infrapopliteal Arteries